This Week in Cancer Cell

Premium

Genetic inactivation of both β2-microglobulin and CD58 allows diffuse large B cell lymphoma to evade the immune system, report Columbia University researchers in Cancer Cell. The researchers found that, in 29 percent of cases, the β2-microglobulin gene is inactivated by mutations and deletions — preventing recognition by CD8+ cytotoxic T cells — and, in 21 percent of cases, the CD58 gene is mutated or deleted — affecting immune responses mediated by T and natural killer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.